JP2025063176A5 - - Google Patents
Info
- Publication number
- JP2025063176A5 JP2025063176A5 JP2025004802A JP2025004802A JP2025063176A5 JP 2025063176 A5 JP2025063176 A5 JP 2025063176A5 JP 2025004802 A JP2025004802 A JP 2025004802A JP 2025004802 A JP2025004802 A JP 2025004802A JP 2025063176 A5 JP2025063176 A5 JP 2025063176A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- pharmaceutically acceptable
- acceptable salt
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893604P | 2019-08-29 | 2019-08-29 | |
| US62/893,604 | 2019-08-29 | ||
| US202063052840P | 2020-07-16 | 2020-07-16 | |
| US63/052,840 | 2020-07-16 | ||
| US202063058188P | 2020-07-29 | 2020-07-29 | |
| US63/058,188 | 2020-07-29 | ||
| PCT/US2020/048194 WO2021041671A1 (en) | 2019-08-29 | 2020-08-27 | Kras g12d inhibitors |
| JP2022513171A JP7622043B2 (ja) | 2019-08-29 | 2020-08-27 | Ｋｒａｓ ｇ１２ｄ阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513171A Division JP7622043B2 (ja) | 2019-08-29 | 2020-08-27 | Ｋｒａｓ ｇ１２ｄ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025063176A JP2025063176A (ja) | 2025-04-15 |
| JP2025063176A5 true JP2025063176A5 (https=) | 2025-10-08 |
Family
ID=74683570
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513171A Active JP7622043B2 (ja) | 2019-08-29 | 2020-08-27 | Ｋｒａｓ ｇ１２ｄ阻害剤 |
| JP2025004802A Pending JP2025063176A (ja) | 2019-08-29 | 2025-01-14 | Ｋｒａｓ ｇ１２ｄ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022513171A Active JP7622043B2 (ja) | 2019-08-29 | 2020-08-27 | Ｋｒａｓ ｇ１２ｄ阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11453683B1 (https=) |
| EP (1) | EP4021444A4 (https=) |
| JP (2) | JP7622043B2 (https=) |
| KR (1) | KR20220071193A (https=) |
| CN (1) | CN114615981B (https=) |
| AU (1) | AU2020337938B2 (https=) |
| BR (1) | BR112022003543A2 (https=) |
| CA (1) | CA3148745A1 (https=) |
| CL (1) | CL2022000447A1 (https=) |
| CO (1) | CO2022003782A2 (https=) |
| IL (1) | IL290845B1 (https=) |
| MX (1) | MX2022002465A (https=) |
| PH (1) | PH12022550469A1 (https=) |
| TW (2) | TWI874443B (https=) |
| WO (1) | WO2021041671A1 (https=) |
| ZA (1) | ZA202202362B (https=) |
Families Citing this family (244)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| WO2023205701A1 (en) | 2022-04-20 | 2023-10-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| WO2022015375A1 (en) * | 2020-07-16 | 2022-01-20 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| EP4192585A4 (en) * | 2020-08-04 | 2024-08-21 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| EP4204412A4 (en) * | 2020-08-26 | 2024-10-09 | InventisBio Co., Ltd. | HETEROARYL COMPOUNDS, PRODUCTION PROCESSES AND USES THEREOF |
| CA3191279A1 (en) | 2020-08-28 | 2022-03-03 | Yi Liu | Heterocyclic compounds and uses thereof |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| WO2022061251A1 (en) * | 2020-09-18 | 2022-03-24 | Plexxikon Inc. | Compounds and methods for kras modulation and indications therefor |
| WO2022068921A1 (zh) * | 2020-09-30 | 2022-04-07 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| WO2022098625A1 (en) | 2020-11-03 | 2022-05-12 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| CA3203080A1 (en) * | 2020-12-22 | 2022-06-30 | Hongqi Tian | Preparation and application method of heterocyclic compound as kras inhibitor |
| JP2024501507A (ja) * | 2020-12-25 | 2024-01-12 | スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド | ケトヘキソキナーゼ阻害剤及びその用途 |
| WO2022170999A1 (zh) * | 2021-02-09 | 2022-08-18 | 南京明德新药研发有限公司 | 吡啶[4，3-d]嘧啶类化合物 |
| WO2022173032A1 (ja) | 2021-02-15 | 2022-08-18 | アステラス製薬株式会社 | Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するためのキナゾリン化合物 |
| EP4293025B1 (en) | 2021-02-15 | 2025-10-29 | Astellas Pharma Inc. | 4-aminoquinazoline compound |
| WO2022184178A1 (en) * | 2021-03-05 | 2022-09-09 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| US20240199644A1 (en) * | 2021-03-07 | 2024-06-20 | Jacobio Pharmaceuticals Co., Ltd. | Fused Ring Derivatives Useful as KRAS G12D Inhibitors |
| JP2024509280A (ja) * | 2021-03-10 | 2024-02-29 | ベータ・ファーマ・インコーポレイテッド | Ｋｒａｓ阻害物質としてのピリドピリミジン誘導体 |
| CN115304603B (zh) * | 2021-05-07 | 2024-04-09 | 药雅科技(上海)有限公司 | 喹唑啉类抑制剂的制备及其应用 |
| CN115073451A (zh) * | 2021-03-15 | 2022-09-20 | 药雅科技(上海)有限公司 | Krasg12d突变蛋白抑制剂的制备及其应用 |
| TWI810803B (zh) * | 2021-03-15 | 2023-08-01 | 大陸商藥雅科技（上海）有限公司 | 突變蛋白抑制劑的製備及其應用 |
| CN116964058A (zh) * | 2021-03-15 | 2023-10-27 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| CN115490689B (zh) * | 2021-06-17 | 2024-04-09 | 药雅科技(上海)有限公司 | 不可逆krasg12c抑制剂的制备及其应用 |
| CN115260214A (zh) * | 2021-04-29 | 2022-11-01 | 药雅科技(上海)有限公司 | 稠环类krasg12d突变蛋白抑制剂的制备及其应用 |
| CN115160309B (zh) * | 2021-04-07 | 2024-04-09 | 药雅科技(上海)有限公司 | Krasg12c突变蛋白杂环类抑制剂的制备及其应用 |
| CN115073450A (zh) * | 2021-03-15 | 2022-09-20 | 药雅科技(上海)有限公司 | Krasg12c突变蛋白抑制剂的制备及其应用 |
| WO2022194191A1 (en) * | 2021-03-16 | 2022-09-22 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heterocyclic compounds as inhibitors of kras g12d |
| CA3211725A1 (en) * | 2021-03-17 | 2022-09-22 | Tao Jiang | Pyrimidine-fused cyclic compound, preparation method therefor and use thereof |
| CN115109078A (zh) * | 2021-03-22 | 2022-09-27 | 苏州泽璟生物制药股份有限公司 | 嘧啶并吡啶类抑制剂及其制备方法和应用 |
| CN115124524A (zh) * | 2021-03-26 | 2022-09-30 | 浙江海正药业股份有限公司 | 三环类衍生物及其制备方法和用途 |
| CN117659051A (zh) * | 2021-03-30 | 2024-03-08 | 上海德琪医药科技有限公司 | Kras g12d蛋白抑制剂和其用途 |
| CN116157400B (zh) * | 2021-03-30 | 2024-10-22 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
| CN115197245A (zh) * | 2021-04-09 | 2022-10-18 | 上海拓界生物医药科技有限公司 | 一种Kras抑制剂及其制备方法 |
| US20250255868A1 (en) * | 2021-04-09 | 2025-08-14 | Hangzhou Innogate Pharma Co., Ltd. | Heterocyclic compound acting as kras g12d inhibitor |
| WO2022217042A1 (en) * | 2021-04-09 | 2022-10-13 | Ikena Oncology, Inc. | Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions |
| WO2022221386A1 (en) * | 2021-04-14 | 2022-10-20 | Erasca, Inc. | Selective kras inhibitors |
| EP4322954A4 (en) * | 2021-04-16 | 2025-01-29 | Merck Sharp & Dohme LLC | SMALL MOLECULAR INHIBITORS OF THE KRAS G12D MUTANT |
| WO2022227987A1 (zh) * | 2021-04-28 | 2022-11-03 | 浙江海正药业股份有限公司 | 杂环类衍生物及其制备方法和用途 |
| US20250059205A1 (en) * | 2021-04-29 | 2025-02-20 | Amgen Inc. | Heterocyclic Compounds and Methods of Use |
| MX2023012725A (es) * | 2021-04-29 | 2024-09-23 | Amgen Inc | Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos. |
| CN115260158A (zh) * | 2021-04-30 | 2022-11-01 | 上海医药集团股份有限公司 | 一种靶向蛋白调节剂的化合物及其应用 |
| CN117203207A (zh) * | 2021-04-30 | 2023-12-08 | 江苏恒瑞医药股份有限公司 | 桥环类化合物、其制备方法及其在医药上的应用 |
| CN117222650A (zh) * | 2021-04-30 | 2023-12-12 | 劲方医药科技(上海)有限公司 | 吡啶或嘧啶并环类化合物，其制法与医药上的用途 |
| JP2024516450A (ja) * | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| WO2022236578A1 (en) * | 2021-05-10 | 2022-11-17 | Nikang Therapeutics, Inc. | Exocyclic amino quinazoline derivatives as kras inhibitors |
| WO2022246092A1 (en) * | 2021-05-21 | 2022-11-24 | Blossomhill Therapeutics, Inc. | Macrocyclic compounds for treating disease |
| US20240300980A1 (en) * | 2021-05-22 | 2024-09-12 | Shanghai Kechow Pharma, Inc. | Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment |
| US20230391785A1 (en) | 2021-05-24 | 2023-12-07 | 280 Bio, Inc. | Nitrogen-containing heterocyclic compound, method for preparing same and use of same |
| CN115385937A (zh) * | 2021-05-25 | 2022-11-25 | 江苏恒瑞医药股份有限公司 | 嘧啶并环烷基类化合物、其制备方法及其在医药上的应用 |
| CN115385938A (zh) * | 2021-05-25 | 2022-11-25 | 江苏恒瑞医药股份有限公司 | 苯并嘧啶类化合物、其制备方法及其在医药上的应用 |
| WO2022247757A1 (zh) * | 2021-05-26 | 2022-12-01 | 南京明德新药研发有限公司 | 氟取代的嘧啶并吡啶类化合物及其应用 |
| BR112023024906A2 (pt) | 2021-05-28 | 2024-02-15 | Redx Pharma Plc | Compostos |
| WO2022261154A1 (en) | 2021-06-09 | 2022-12-15 | Eli Lilly And Company | Substituted fused azines as kras g12d inhibitors |
| BR112023025869A2 (pt) | 2021-06-10 | 2024-02-27 | Redx Pharma Plc | Derivados de quinazolina úteis como inibidores de ras |
| CN115466272A (zh) * | 2021-06-11 | 2022-12-13 | 博瑞生物医药（苏州）股份有限公司 | 一种嘧啶并杂环化合物，包含其的药物组合物及其用途 |
| WO2022262686A1 (en) * | 2021-06-13 | 2022-12-22 | Jingrui Biopharma Co., Ltd. | Kras g12d inhibitors |
| US20240383921A1 (en) * | 2021-06-16 | 2024-11-21 | Erasca, Inc. | Amide and urea-containing tricyclic kras inhibitors |
| WO2022266069A1 (en) * | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Tricyclic kras g12d inhibitors |
| TW202317580A (zh) * | 2021-06-18 | 2023-05-01 | 大陸商南京燧坤智能科技有限公司 | 用作ｋｒａｓ ｇ１２ｄ抑制劑的氘代化合物 |
| EP4361157A4 (en) * | 2021-06-21 | 2024-10-16 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | FUSED TETRACYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS USE IN MEDICINE |
| WO2022271823A1 (en) * | 2021-06-23 | 2022-12-29 | Newave Pharmaceutical Inc. | Mutant kras modulators and uses thereof |
| JP2024524524A (ja) * | 2021-06-30 | 2024-07-05 | 上海艾力斯医薬科技股▲ふん▼有限公司 | 窒素含有複素環化合物、その製造方法、中間体及び使用 |
| AU2022303440A1 (en) * | 2021-07-02 | 2024-02-22 | Shanghai De Novo Pharmatech Co., Ltd. | Kras g12d inhibitor and use thereof |
| CN117460737A (zh) * | 2021-07-05 | 2024-01-26 | 四川科伦博泰生物医药股份有限公司 | 杂芳环化合物、其制备方法及用途 |
| CN117751116A (zh) * | 2021-07-07 | 2024-03-22 | 微境生物医药科技(上海)有限公司 | 作为KRas G12D抑制剂的稠环化合物 |
| TW202317589A (zh) * | 2021-07-14 | 2023-05-01 | 美商尼坎醫療公司 | 作為ｋｒａｓ抑制劑的伸烷基衍生物 |
| WO2023284537A1 (en) * | 2021-07-16 | 2023-01-19 | Shanghai Zion Pharma Co. Limited | Kras g12d inhibitors and uses thereof |
| WO2023284881A1 (en) * | 2021-07-16 | 2023-01-19 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds useful as kras g12d inhibitors |
| WO2023283933A1 (en) * | 2021-07-16 | 2023-01-19 | Silexon Biotech Co., Ltd. | Compounds useful as kras g12d inhibitors |
| WO2023001141A1 (en) * | 2021-07-23 | 2023-01-26 | Shanghai Zion Pharma Co. Limited | Kras g12d inhibitors and uses thereof |
| WO2023018812A1 (en) * | 2021-08-10 | 2023-02-16 | Amgen Inc. | Heterocyclic compounds and methods of use |
| TW202321261A (zh) * | 2021-08-10 | 2023-06-01 | 美商伊瑞斯卡公司 | 選擇性ｋｒａｓ抑制劑 |
| JP2024532735A (ja) * | 2021-08-10 | 2024-09-10 | アムジエン・インコーポレーテツド | 複素環式化合物及び使用方法 |
| CN116669740A (zh) * | 2021-08-16 | 2023-08-29 | 华润医药研究院（深圳）有限公司 | 嘧啶并吡啶类化合物及其制备方法和医药用途 |
| WO2023020523A1 (en) * | 2021-08-18 | 2023-02-23 | Jacobio Pharmaceuticals Co., Ltd. | Bicyclic derivatives and use thereof |
| WO2023020521A1 (en) * | 2021-08-18 | 2023-02-23 | Jacobio Pharmaceuticals Co., Ltd. | Pyridine fused pyrimidine derivatives and use thereof |
| UY39906A (es) * | 2021-08-18 | 2023-03-31 | Jacobio Pharmaceuticals Co Ltd | Derivados de 1,4-oxazepano y usos de los mismos |
| CN116323625A (zh) * | 2021-08-25 | 2023-06-23 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| WO2023030495A1 (en) * | 2021-09-03 | 2023-03-09 | Ascentage Pharma (Suzhou) Co., Ltd. | Kras inhibitors |
| CN115785124B (zh) * | 2021-09-10 | 2024-11-08 | 润佳（苏州）医药科技有限公司 | Kras g12d抑制剂及其用途 |
| CN116284055B (zh) * | 2021-09-10 | 2025-09-23 | 润佳（苏州）医药科技有限公司 | 一种kras抑制剂及其用途 |
| US20240409558A1 (en) | 2021-09-13 | 2024-12-12 | Biomea Fusion, Inc. | Irreversible inhibitors of kras |
| CN116143805B (zh) * | 2021-09-17 | 2025-10-17 | 上海凌达生物医药有限公司 | 一类含氮杂环联芳基类化合物、制备方法和用途 |
| WO2023051586A1 (zh) * | 2021-09-29 | 2023-04-06 | 先声再明医药有限公司 | Kras g12d抑制剂化合物及其制备方法和应用 |
| AU2022361380A1 (en) | 2021-10-05 | 2024-04-11 | Mirati Therapeutics, Inc. | Combination therapies of kras g12d inhibitors with sos1 inhibitors |
| MX2024004216A (es) | 2021-10-05 | 2024-06-20 | Mirati Therapeutics Inc | Terapias combinadas de inhibidores de kras g12d con inhibidores de la familia pan erbb. |
| IL311834A (en) | 2021-10-05 | 2024-05-01 | Mirati Therapeutics Inc | Combinations of KRAS G12D inhibitors with PI3KA inhibitors and therapeutic methods |
| CN118401254A (zh) | 2021-10-05 | 2024-07-26 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂与shp-2抑制剂的组合疗法 |
| AU2022361219A1 (en) | 2021-10-05 | 2024-04-11 | Mirati Therapeutics, Inc. | Combinations of kras g12d inhibitors with irinotecan and related methods of treatment |
| WO2023056951A1 (zh) * | 2021-10-08 | 2023-04-13 | 杭州德睿智药科技有限公司 | 芳基取代并杂环化合物 |
| WO2023061294A1 (zh) * | 2021-10-13 | 2023-04-20 | 再鼎医药(上海)有限公司 | 含氮杂环类衍生物调节剂、其制备方法及应用 |
| WO2023061463A1 (zh) * | 2021-10-15 | 2023-04-20 | 广东东阳光药业有限公司 | 新的嘧啶并吡啶化合物、其药物组合物及其用途 |
| WO2023072188A1 (zh) * | 2021-10-29 | 2023-05-04 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| WO2023077441A1 (en) * | 2021-11-05 | 2023-05-11 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
| EP4436571A4 (en) * | 2021-11-24 | 2025-10-15 | Merck Sharp & Dohme Llc | SMALL MOLECULE INHIBITORS OF KRAS MUTATIONAL PROTEINS |
| US20250250286A1 (en) * | 2021-11-30 | 2025-08-07 | Beta Pharma, Inc. | Fused pyrimidine derivatives as kras oncoprotein inhibitors |
| WO2023098425A1 (zh) | 2021-12-02 | 2023-06-08 | 上海和誉生物医药科技有限公司 | 一种kras抑制剂及其制备和在药学上的应用 |
| CN117940436A (zh) * | 2021-12-02 | 2024-04-26 | 上海和誉生物医药科技有限公司 | 一种7-(萘-1-基)吡啶并[4,3-d]嘧啶衍生物及其制备和应用 |
| CN116217591A (zh) * | 2021-12-02 | 2023-06-06 | 思路迪生物医药(上海)有限公司 | 一类作为kras g12d突变抑制剂的吡啶并嘧啶类衍生物 |
| WO2023103906A1 (zh) * | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| CN116253748A (zh) * | 2021-12-09 | 2023-06-13 | 苏州浦合医药科技有限公司 | 取代的双环杂芳基化合物作为kras g12d抑制剂 |
| EP4452974A4 (en) * | 2021-12-21 | 2025-11-19 | Bridgene Biosciences Inc | RAS ONCOPROTEIN INHIBITORS |
| CN116332959A (zh) * | 2021-12-24 | 2023-06-27 | 苏州泽璟生物制药股份有限公司 | Krasg12d蛋白水解调节剂及其制备方法和应用 |
| WO2023119677A1 (en) * | 2021-12-24 | 2023-06-29 | Astellas Pharma Inc. | Pharmaceutical composition comprising a quinazoline compound |
| WO2023125989A1 (zh) * | 2021-12-31 | 2023-07-06 | 上海医药集团股份有限公司 | 一种喹唑啉类化合物及其应用 |
| CN118434747A (zh) * | 2022-01-11 | 2024-08-02 | 上海艾力斯医药科技股份有限公司 | 一种含氮杂环化合物、其制备方法、中间体及应用 |
| WO2023137223A1 (en) * | 2022-01-17 | 2023-07-20 | Newave Pharmaceutical Inc. | Pan-kras inhibitors and uses thereof |
| EP4371991A4 (en) | 2022-01-21 | 2025-02-26 | Usynova Pharmaceuticals Ltd. | Benzopyrimidine compounds and use thereof |
| CN118556063A (zh) * | 2022-01-21 | 2024-08-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| WO2023138524A1 (zh) * | 2022-01-24 | 2023-07-27 | 贝达药业股份有限公司 | Kras g12d降解剂及其在医药上的应用 |
| WO2023143312A1 (zh) * | 2022-01-28 | 2023-08-03 | 上海艾力斯医药科技股份有限公司 | 一种含氮杂环化合物、其制备方法及应用 |
| EP4471037A1 (en) | 2022-01-30 | 2024-12-04 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinoline compound and use thereof |
| AU2023216698A1 (en) * | 2022-02-03 | 2024-06-13 | Mirati Therapeutics, Inc. | Quinazoline pan-kras inhibitors |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| WO2023152255A1 (en) | 2022-02-10 | 2023-08-17 | Bayer Aktiengesellschaft | Fused pyrimidines as kras inhibitors |
| WO2023151621A1 (zh) * | 2022-02-11 | 2023-08-17 | 泰励生物科技（上海）有限公司 | 具有抗kras突变肿瘤活性的化合物 |
| WO2023173014A1 (en) * | 2022-03-09 | 2023-09-14 | Blossomhill Therapeutics, Inc. | Kras inhibitors and their use |
| CN116891514A (zh) * | 2022-04-06 | 2023-10-17 | 润佳（苏州）医药科技有限公司 | 一种双官能化合物及其用途 |
| US20240059712A1 (en) * | 2022-03-09 | 2024-02-22 | Risen (Suzhou) Pharma Tech Co., Ltd. | Bifunctional compounds and pharmaceutical uses thereof |
| TW202346270A (zh) | 2022-03-11 | 2023-12-01 | 日商安斯泰來製藥股份有限公司 | 用於誘發g12d突變kras蛋白分解之雜環化合物 |
| AU2023231139A1 (en) | 2022-03-11 | 2024-09-05 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| CN117659049A (zh) * | 2022-08-23 | 2024-03-08 | 苏州泽璟生物制药股份有限公司 | 取代桥环类抑制剂及其制备方法和应用 |
| WO2023179629A1 (zh) * | 2022-03-22 | 2023-09-28 | 苏州泽璟生物制药股份有限公司 | 取代桥环类抑制剂及其制备方法和应用 |
| MX2024011631A (es) | 2022-03-25 | 2024-09-30 | Lilly Co Eli | Inhibidores de kras. |
| EP4473970A4 (en) | 2022-03-31 | 2026-01-21 | Eisai R&D Man Co Ltd | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUMORS |
| WO2023198078A1 (zh) * | 2022-04-11 | 2023-10-19 | 杭州英创医药科技有限公司 | 作为kras g12d抑制剂的多环化合物 |
| CN116891488B (zh) | 2022-04-11 | 2025-12-12 | 成都海博为药业有限公司 | 稠环化合物、包含其的药物组合物及应用 |
| CN118434748A (zh) * | 2022-04-15 | 2024-08-02 | 杭州多域生物技术有限公司 | 一种六元并六元化合物、制备方法、药物组合物和应用 |
| CR20240451A (es) | 2022-04-21 | 2024-12-04 | Gilead Sciences Inc | Compuestos de modulación de kras g12d |
| WO2023212548A1 (en) * | 2022-04-26 | 2023-11-02 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2023212549A1 (en) * | 2022-04-26 | 2023-11-02 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CA3247639A1 (en) | 2022-05-06 | 2023-11-09 | PAQ Therapeutics Inc. | CHIMERAS TARGET KRAS-G12D PROTEOLYSIS |
| WO2023213269A1 (en) * | 2022-05-06 | 2023-11-09 | Zai Lab (Shanghai) Co., Ltd. | Amide-substituted heterocyclic compounds as kras g12d modulators and uses thereof |
| WO2023220421A1 (en) * | 2022-05-13 | 2023-11-16 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Inhibitors of kras(g12d) |
| CR20240508A (es) * | 2022-05-19 | 2024-12-20 | Genentech Inc | Compuestos aza-tetracíclicos de oxazepina y usos de los mismos |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| CN114907387B (zh) * | 2022-05-26 | 2023-11-10 | 中山大学 | 嘧啶并吡咯类kras抑制剂及其制备方法与应用 |
| CN119630676A (zh) | 2022-06-10 | 2025-03-14 | 百时美施贵宝公司 | 作为kras抑制剂的吡啶并[4,3-d]嘧啶衍生物 |
| EP4540244A1 (en) * | 2022-06-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Prodrugs of pan-kras inhibitors |
| WO2023246903A1 (zh) * | 2022-06-24 | 2023-12-28 | 暨南大学 | 含硒杂环类化合物及其药用组合物和应用 |
| WO2024001839A1 (zh) * | 2022-06-29 | 2024-01-04 | 四川科伦博泰生物医药股份有限公司 | 杂芳环化合物、其制备方法及用途 |
| CN117327102B (zh) * | 2022-06-30 | 2026-04-28 | 重庆华森英诺生物科技有限公司 | Kras抑制剂、其制备方法及应用 |
| WO2024008068A1 (en) * | 2022-07-04 | 2024-01-11 | Jacobio Pharmaceuticals Co., Ltd. | K-ras mutant protein inhibitors |
| AU2023302139A1 (en) | 2022-07-05 | 2024-12-19 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
| WO2024008179A1 (en) * | 2022-07-07 | 2024-01-11 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| TW202408520A (zh) * | 2022-07-08 | 2024-03-01 | 大陸商貝達藥業股份有限公司 | Kras g12d抑制劑及其在醫藥上的應用 |
| CN117466796A (zh) * | 2022-07-20 | 2024-01-30 | 上海皓鸿生物医药科技有限公司 | 一种((2R,7aS)-2-氟六氢-1H-吡咯嗪-7a-基)甲醇的制备方法 |
| US20250145631A1 (en) | 2022-07-21 | 2025-05-08 | Astellas Pharma Inc. | Heterocyclic compound acting on g12d mutant kras protein |
| WO2024022444A1 (zh) | 2022-07-27 | 2024-02-01 | 江苏恒瑞医药股份有限公司 | 稠环类化合物、其制备方法及其在医药上的应用 |
| AU2023314335A1 (en) | 2022-07-29 | 2025-02-27 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutical composition comprising kras g12d inhibitor |
| CN119585278A (zh) * | 2022-08-05 | 2025-03-07 | 杭州中美华东制药有限公司 | 具有KRas G12D抑制作用的化合物 |
| IL318647A (en) | 2022-08-05 | 2025-03-01 | Kumquat Biosciences Inc | Heterocyclic compounds and their uses |
| TW202412789A (zh) | 2022-08-05 | 2024-04-01 | 日商安斯泰來製藥股份有限公司 | 用於誘導突變kras蛋白分解之雜環化合物 |
| JP2025526744A (ja) | 2022-08-11 | 2025-08-15 | ブリストル－マイヤーズ スクイブ カンパニー | Ｋｒａｓ阻害剤 |
| WO2024034123A1 (ja) * | 2022-08-12 | 2024-02-15 | アステラス製薬株式会社 | 複素環化合物を含む医薬組成物 |
| JP2025527530A (ja) * | 2022-08-16 | 2025-08-22 | ブリストル－マイヤーズ スクイブ カンパニー | Ｋｒａｓ阻害剤 |
| EP4573095A1 (en) | 2022-08-17 | 2025-06-25 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| US20260070929A1 (en) * | 2022-08-24 | 2026-03-12 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for modulating kras(g12d) |
| WO2024045066A1 (en) * | 2022-08-31 | 2024-03-07 | Nikang Therapeutics, Inc. | Alkylidene carbamate as kras inhibitors |
| EP4584276A1 (en) * | 2022-09-07 | 2025-07-16 | Bristol-Myers Squibb Company | Kras g12d inhibitors |
| WO2024054625A2 (en) * | 2022-09-08 | 2024-03-14 | Nikang Therapeutics, Inc. | Bifunctional compounds for degrading kras g12d via ubiquitin proteasome pathway |
| TW202426463A (zh) * | 2022-09-09 | 2024-07-01 | 大陸商上海翰森生物醫藥科技有限公司 | 含嘧啶多環類生物抑制劑、其製備方法和應用 |
| TW202416976A (zh) * | 2022-09-16 | 2024-05-01 | 大陸商南京明德新藥研發有限公司 | 含六氫螺環［環丙烷—１，２＇—吡咯𠯤］的化合物 |
| WO2024061333A1 (zh) * | 2022-09-21 | 2024-03-28 | 甘李药业股份有限公司 | 一种kras突变蛋白抑制剂、及其制备方法和应用 |
| JP2025534419A (ja) | 2022-09-30 | 2025-10-15 | トラスヴェダ リミテッド | Ｋｒａｓ変異腫瘍に対する抗腫瘍活性を有する化合物 |
| EP4631942A1 (en) | 2022-10-21 | 2025-10-15 | Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Pan-kras degrading agent, and preparation method therefor and use thereof |
| JP2025536369A (ja) * | 2022-10-21 | 2025-11-05 | リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド | Ｋｒａｓ ｇ１２ｄ分解剤及びその製造方法並びに応用 |
| WO2024092420A1 (zh) * | 2022-10-31 | 2024-05-10 | 上海皓元医药股份有限公司 | 一种((2R,7aS)-2-氟六氢-1H-吡咯嗪-7a-基)甲醇的制备方法 |
| AU2023382606A1 (en) | 2022-11-14 | 2025-05-08 | Amgen Inc. | Macrocyclic kras inhibitors and methods of use |
| TW202430179A (zh) | 2022-11-21 | 2024-08-01 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ＫＲａｓ抑制劑 |
| KR20250113487A (ko) | 2022-11-28 | 2025-07-25 | 레드엑스 파마 리미티드 | 화합물 |
| CN116554208A (zh) * | 2022-12-02 | 2023-08-08 | 苏州浦合医药科技有限公司 | 取代的双环杂芳基化合物作为kras g12d抑制剂 |
| WO2024123102A1 (ko) * | 2022-12-07 | 2024-06-13 | 에스케이바이오팜 주식회사 | Kras g12d 저해제로서 신규한 3환 화합물 및 이의 용도 |
| EP4640689A1 (en) | 2022-12-20 | 2025-10-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystal form of kras g12d inhibitor and preparation method therefor |
| EP4640684A1 (en) | 2022-12-23 | 2025-10-29 | Abbisko Therapeutics Co., Ltd. | Kras g12d inhibitors and uses thereof |
| CN115894503B (zh) * | 2022-12-30 | 2025-06-13 | 合肥诺全医药有限公司 | 一种氮杂环戊烷衍生物的制备方法 |
| WO2024158242A1 (ko) * | 2023-01-25 | 2024-08-02 | 주식회사 엔바이오스 | Kras g12d 돌연변이 억제용 화합물 및 이를 유효성분으로 포함하는 암질환 예방 또는 치료용 조성물 |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| WO2024179546A1 (en) * | 2023-03-01 | 2024-09-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Kras inhibitors |
| WO2024186680A1 (en) * | 2023-03-03 | 2024-09-12 | Frontier Medicines Corporation | Methods for preparing pyrrolizidine compounds |
| KR20260041941A (ko) * | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
| KR20250164300A (ko) | 2023-03-30 | 2025-11-24 | 일라이 릴리 앤드 캄파니 | KRas 억제제 |
| US20240368193A1 (en) | 2023-03-31 | 2024-11-07 | Eli Lilly And Company | Kras inhibitors |
| AU2023439518A1 (en) | 2023-04-06 | 2025-08-28 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| EP4678643A1 (en) | 2023-04-14 | 2026-01-14 | Sunshine Lake Pharma Co., Ltd. | Kras inhibitor compound, pharmaceutical composition thereof, and use thereof |
| EP4709729A1 (en) | 2023-05-12 | 2026-03-18 | Jazz Pharmaceuticals Ireland Ltd. | Pyrazolo[4,3-f]quinazoline derivatives as modulators of g12d mutant kras useful for the treatment of cancer |
| CN121487732A (zh) * | 2023-05-12 | 2026-02-06 | 荣山医药股份有限公司 | 用于治疗疾病的稠环kras抑制剂 |
| CN121532183A (zh) * | 2023-05-15 | 2026-02-13 | 米拉蒂治疗公司 | Kras g12s和g12c抑制剂 |
| WO2024243186A2 (en) * | 2023-05-22 | 2024-11-28 | Board Of Regents, The University Of Texas System | Heterocyclic compounds as nras inhibitors |
| PE20252789A1 (es) | 2023-05-24 | 2025-12-22 | Kumquat Biosciences Inc | Compuestos heterociclicos y usos de estos |
| CN121605110A (zh) | 2023-06-06 | 2026-03-03 | 金橘生物科技公司 | 取代杂环化合物及其用途 |
| AR133027A1 (es) | 2023-06-22 | 2025-08-20 | Astellas Pharma Inc | Composición farmacéutica que comprende un compuesto de quinazolina |
| AR133028A1 (es) | 2023-06-22 | 2025-08-20 | Astellas Pharma Inc | Composición farmacéutica que comprende un degradador de todas las kras |
| CN121399088A (zh) * | 2023-07-13 | 2026-01-23 | 上海森辉医药有限公司 | Kras g12d中间体的制备方法 |
| WO2025016899A1 (en) | 2023-07-19 | 2025-01-23 | Bayer Aktiengesellschaft | Spirocyclic compounds for the treatment of cancer |
| CN121843946A (zh) * | 2023-07-24 | 2026-04-10 | 米拉蒂治疗公司 | Mrtx1133合成的方法和中间体 |
| WO2025026903A1 (en) | 2023-07-31 | 2025-02-06 | Bayer Aktiengesellschaft | Imidazo pyrimidine compounds for the treatment of cancer |
| CN121909197A (zh) | 2023-08-22 | 2026-04-21 | 赛诺菲 | 2-(3,8-二氮杂双环[3.2.1]辛-3-基)-1,3,5-三嗪衍生物作为用于治疗癌症的kras g12d抑制剂 |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| US20250101043A1 (en) | 2023-09-27 | 2025-03-27 | Eli Lilly And Company | Kras inhibitors |
| CN121941690A (zh) | 2023-10-03 | 2026-04-28 | Paq医疗公司 | Kras蛋白水解靶向嵌合体 |
| CN121969634A (zh) * | 2023-10-08 | 2026-05-01 | 成都海博为药业有限公司 | 一种稠环化合物及应用 |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| WO2025077770A1 (zh) * | 2023-10-10 | 2025-04-17 | 成都海博为药业有限公司 | 一种稠环化合物及在kras抑制剂方面的应用 |
| WO2025080956A1 (en) | 2023-10-12 | 2025-04-17 | Mirati Therapeutics, Inc. | Mrtx1133 pharmaceutical compositions |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025107579A1 (zh) * | 2023-11-20 | 2025-05-30 | 贝达药业股份有限公司 | 一种靶向泛kras蛋白降解剂的化合物及其应用 |
| CN117683052A (zh) * | 2023-12-07 | 2024-03-12 | 上海相辉医药科技有限公司 | 一种kras g12d抑制剂mrtx1133的制备方法 |
| CN117756640B (zh) * | 2023-12-14 | 2025-09-26 | 江苏宝众宝达药业股份有限公司 | 一种两步升温法制备高纯度3,3'-二氨基联苯胺的方法 |
| WO2025136346A1 (en) * | 2023-12-19 | 2025-06-26 | Amgen Inc. | Indazole containing compounds and methods of use |
| KR102738924B1 (ko) * | 2023-12-26 | 2024-12-06 | 주식회사 베노바이오 | Kras g12d 변이가 존재하는 암 치료를 위한 신규한 화합물 및 이를 이용한 암의 예방 또는 치료용 조성물 |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| CN119661556B (zh) * | 2024-01-26 | 2025-12-09 | 苏州盛迪亚生物医药有限公司 | 一种稠环类化合物的可药用盐、其结晶形式及用途 |
| WO2025163494A1 (en) | 2024-01-29 | 2025-08-07 | Jazz Pharmaceuticals Ireland Ltd. | Condensed azines for the treatment of cancer |
| WO2025170938A1 (en) * | 2024-02-06 | 2025-08-14 | Windermere Therapeutics, Inc. | Kras(g12d) inhibitors |
| WO2025194054A1 (en) * | 2024-03-14 | 2025-09-18 | Amgen Inc. | Spirocyclic compounds as modulators of kras and uses thereof |
| TW202602882A (zh) * | 2024-03-14 | 2026-01-16 | 美商安進公司 | 作為ｋｒａｓ調節劑的大環化合物及其用途 |
| WO2025217015A1 (en) | 2024-04-08 | 2025-10-16 | Mirati Therapeutics, Inc. | Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer |
| WO2025231310A1 (en) | 2024-05-03 | 2025-11-06 | Mirati Therapeutics, Inc. | Crystalline forms of mrtx1133 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025253326A1 (ko) * | 2024-06-05 | 2025-12-11 | 에스케이바이오팜 주식회사 | Kras 저해제로서 신규한 3환 화합물 및 이의 용도 |
| WO2026059955A1 (en) | 2024-09-11 | 2026-03-19 | Eli Lilly And Company | (3-((6-(2-amino-benzo[d]thiazol-4-yl)-3-(pyrrolidin-1-yl)-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)amino)- piperidin-2-one derivatives as kras inhibitors for the treatment of cancer |
| WO2026075942A1 (en) | 2024-10-01 | 2026-04-09 | Eli Lilly And Company | Kras inhibitors |
| WO2026075945A1 (en) | 2024-10-01 | 2026-04-09 | Eli Lilly And Company | Kras inhibitors |
| WO2026080796A1 (en) | 2024-10-11 | 2026-04-16 | Mirati Therapeutics, Inc. | Mrtx1133 capsule pharmaceutical compositions |
Family Cites Families (207)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002053558A1 (en) | 2001-01-02 | 2002-07-11 | F.Hoffman-La Roche Ag | Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| US7105667B2 (en) | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
| US20080051387A1 (en) | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
| WO2008009078A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| EP2518063B1 (en) | 2006-12-21 | 2017-02-01 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
| WO2008103470A2 (en) | 2007-02-21 | 2008-08-28 | Trustees Of Columbia University In The City Of New York | Oncogenic-ras-signal dependent lethal compounds |
| US20100298289A1 (en) | 2007-10-09 | 2010-11-25 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| CA2729045A1 (en) | 2008-07-31 | 2010-02-04 | Philippe Bergeron | Pyrimidine compounds, compositions and methods of use |
| WO2010120996A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| JP2012524800A (ja) | 2009-04-22 | 2012-10-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド |
| EP2518064A1 (en) | 2009-12-25 | 2012-10-31 | Mochida Pharmaceutical Co., Ltd. | Novel aryl urea derivative |
| JP2013516422A (ja) | 2009-12-30 | 2013-05-13 | アビラ セラピューティクス， インコーポレイテッド | タンパク質のリガンド−指向性共有的修飾 |
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| HUE039713T2 (hu) | 2012-06-08 | 2019-02-28 | Sensorion | H4 receptor inhibitorok tinnitus kezelésére |
| US9695133B2 (en) | 2012-07-13 | 2017-07-04 | The Trustees Of Columbia University In The City Of New York | Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use |
| CA2904393A1 (en) | 2013-03-15 | 2014-09-25 | Araxes Pharma Llc | Covalent inhibitors of kras g12c |
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| US9745319B2 (en) | 2013-03-15 | 2017-08-29 | Araxes Pharma Llc | Irreversible covalent inhibitors of the GTPase K-Ras G12C |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| EP3055290B1 (en) | 2013-10-10 | 2019-10-02 | Araxes Pharma LLC | Inhibitors of kras g12c |
| MA40074A (fr) | 2014-05-30 | 2015-12-03 | Univ Columbia | Composés liant ras multivalents |
| WO2016025650A1 (en) | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| US10017540B2 (en) | 2015-03-11 | 2018-07-10 | California Institute Of Technology | Cyclic peptide binder against oncogenic K-Ras |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
| US10421764B2 (en) | 2015-04-24 | 2019-09-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Mutant KRas inhibitors |
| AU2016258192B2 (en) | 2015-05-06 | 2021-07-29 | Leidos Biomedical Research, Inc. | K-Ras modulators |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| CN108513588A (zh) | 2015-09-24 | 2018-09-07 | Ionis制药公司 | Kras表达的调节剂 |
| EP3356351A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058805A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058728A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356359B1 (en) | 2015-09-28 | 2021-10-20 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356349A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
| EP3365686A4 (en) | 2015-10-22 | 2019-03-27 | The Scripps Research Institute | REACTIVE CYSTEINSONS AND USES THEREOF |
| WO2017080980A1 (en) | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer |
| WO2017079864A1 (en) | 2015-11-12 | 2017-05-18 | Hangzhou Yier Biotech Co., Ltd. | Treatment of cancers related to chronically active ras |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| US9988357B2 (en) | 2015-12-09 | 2018-06-05 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US20170283445A1 (en) | 2016-04-05 | 2017-10-05 | University Of South Carolina | Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins |
| KR102444509B1 (ko) * | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| WO2018064510A1 (en) | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3523289A1 (en) | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| CA3081983A1 (en) | 2016-11-30 | 2018-06-07 | Bantam Pharmaceutical, Llc | Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases |
| US12150934B2 (en) | 2016-11-30 | 2024-11-26 | Bantam Pharmaceutical, Llc | Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases |
| KR20190095355A (ko) | 2016-12-15 | 2019-08-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 암의 치료를 위한 조성물 및 방법 |
| EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| CN110366550A (zh) | 2016-12-22 | 2019-10-22 | 美国安进公司 | 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物 |
| US10344026B2 (en) | 2017-01-18 | 2019-07-09 | Nantbio, Inc. | Compositions and methods of targeting mutant K-ras |
| WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| JP7327802B2 (ja) | 2017-01-26 | 2023-08-16 | アラクセス ファーマ エルエルシー | 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法 |
| EP3573966A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused n-heterocyclic compounds and methods of use thereof |
| JOP20190186A1 (ar) | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| EP3612526A2 (en) | 2017-04-20 | 2020-02-26 | The Regents of the University of California | K-ras modulators |
| AU2018329920B2 (en) * | 2017-09-08 | 2022-12-01 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| EP3832583A4 (en) | 2018-07-31 | 2021-12-08 | Honda Motor Co., Ltd. | PERFORMANCE FORECAST SYSTEM, PERFORMANCE FORECAST DEVICE, PERFORMANCE FORECAST METHOD, PROGRAM AND STORAGE MEDIUM |
| CN109413550B (zh) | 2018-09-30 | 2021-03-09 | 华为技术有限公司 | 音频播放电路和终端 |
| CN111193490B (zh) | 2018-11-14 | 2025-05-13 | 天津大学 | 散热结构、带散热结构的体声波谐振器、滤波器和电子设备 |
| EP3908283A4 (en) * | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| US20220193242A1 (en) | 2019-02-07 | 2022-06-23 | The Regents Of The University Of California | Immunophilin-dependent inhibitors and uses thereof |
| US20220221355A1 (en) | 2019-02-11 | 2022-07-14 | Mesomat Inc. | Sensing fibers for structural health monitoring |
| KR102747104B1 (ko) | 2019-02-18 | 2024-12-27 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물 |
| CN114026116A (zh) | 2019-02-20 | 2022-02-08 | 弗雷德哈钦森癌症研究中心 | Ras新抗原特异性结合蛋白及其用途 |
| GB201902392D0 (en) | 2019-02-21 | 2019-04-10 | Cambridge Entpr Ltd | Modular binding proteins |
| WO2020176693A2 (en) | 2019-02-26 | 2020-09-03 | Cell Response, Inc. | Methods for treating map3k8 positive cancers |
| WO2020177629A1 (zh) | 2019-03-01 | 2020-09-10 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物，其制法与医药上的用途 |
| KR102934231B1 (ko) | 2019-03-05 | 2026-03-06 | 아스트라제네카 아베 | 항암제로 유용한 융합 삼환식 화합물 |
| US12117170B2 (en) | 2019-03-05 | 2024-10-15 | Questor Technology Inc. | Gas incinerator system |
| EP3941938A1 (en) | 2019-03-06 | 2022-01-26 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to b-cell maturation antigen for treatment of cancer |
| US20220160714A1 (en) | 2019-03-22 | 2022-05-26 | Icahn School Of Medicine At Mount Sinai | Methods for treating colorectal cancer |
| BR112021018739A2 (pt) | 2019-03-29 | 2022-05-03 | Dicerna Pharmaceuticals Inc | Composições e métodos para o tratamento de doenças ou distúrbios associados a kras |
| CA3134825A1 (en) | 2019-03-29 | 2020-10-08 | Kura Oncology, Inc. | Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors |
| KR102222693B1 (ko) | 2019-04-04 | 2021-03-04 | 금정제약 주식회사 | H-rev107 유래 펩타이드의 신규한 용도 |
| WO2020214537A1 (en) | 2019-04-15 | 2020-10-22 | Tosk, Inc. | Modulators of ras gtpase |
| US20200335182A1 (en) | 2019-04-16 | 2020-10-22 | Uratim Ltd. | Method and apparatus for facilitating the binding of biological macromolecules with the use of gluing molecular agents with applications in RAS mutations and related conditions |
| KR20220012255A (ko) | 2019-04-28 | 2022-02-03 | 젠플리트 테라퓨틱스 (상하이) 아이엔씨. | 옥사아자퀴나졸린-7(8h)-케톤 화합물, 이의 제조 방법 및 이의 약학적 응용 |
| US11518758B2 (en) | 2019-05-10 | 2022-12-06 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| PE20220597A1 (es) | 2019-05-10 | 2022-04-22 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos |
| EP3969449B1 (en) | 2019-05-13 | 2025-02-12 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| JP7502337B2 (ja) | 2019-05-20 | 2024-06-18 | カリフォルニア インスティチュート オブ テクノロジー | Ｋｒａｓ ｇ１２ｃインヒビター及びその使用 |
| AU2020277398B2 (en) | 2019-05-21 | 2026-01-29 | Amgen Inc. | Solid state forms |
| CN114437065A (zh) | 2019-05-21 | 2022-05-06 | 益方生物科技(上海)股份有限公司 | 杂环化合物，其制备方法和用途 |
| WO2020234103A1 (en) | 2019-05-21 | 2020-11-26 | Bayer Aktiengesellschaft | Identification and use of kras inhibitors |
| WO2020236947A1 (en) | 2019-05-21 | 2020-11-26 | Amgen Inc. | Solid state forms |
| US12577278B2 (en) | 2019-06-07 | 2026-03-17 | Emory University | KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto |
| CA3141405A1 (en) | 2019-06-12 | 2020-12-17 | H. Charles Manning | Amino acid transport inhibitors and the uses thereof |
| CN114269715A (zh) | 2019-06-12 | 2022-04-01 | 范德比尔特大学 | 作为氨基酸转运抑制剂的二苄基胺 |
| WO2021000885A1 (zh) | 2019-07-01 | 2021-01-07 | 江苏恒瑞医药股份有限公司 | 喹唑啉酮类衍生物、其制备方法及其在医药上的应用 |
| JP7756069B6 (ja) | 2019-08-02 | 2025-11-27 | 上海済▲ユウ▼医薬科技股▲フン▼有限公司 | 四環式化合物、その調製と使用の方法 |
| CN112341457A (zh) | 2019-08-07 | 2021-02-09 | 北京加科思新药研发有限公司 | Kras突变蛋白抑制剂 |
| CN114174298B (zh) | 2019-08-14 | 2023-08-01 | 正大天晴药业集团南京顺欣制药有限公司 | 哒嗪酮并嘧啶类衍生物及其医药用途 |
| CN112390797A (zh) | 2019-08-15 | 2021-02-23 | 微境生物医药科技(上海)有限公司 | 新型螺环类K-Ras G12C抑制剂 |
| WO2021031952A1 (zh) | 2019-08-16 | 2021-02-25 | 劲方医药科技(上海)有限公司 | 氧代六元环并嘧啶类化合物，其制法与医药上的用途 |
| MX2022002108A (es) | 2019-08-22 | 2022-03-17 | Univ Michigan Regents | Metodo para tratar canceres asociados con kras. |
| CN114269735B (zh) | 2019-08-26 | 2024-02-23 | 南京创济生物医药有限公司 | 二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用 |
| MX2022002465A (es) * | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021043322A1 (zh) | 2019-09-06 | 2021-03-11 | 正大天晴药业集团南京顺欣制药有限公司 | 氮杂环庚烷并嘧啶类衍生物及其医药用途 |
| EP3819300A4 (en) | 2019-09-06 | 2021-11-24 | Wellmarker Bio Co., Ltd. | THERAPEUTIC COMPOSITION BASED ON BIOMARKERS |
| WO2021050732A1 (en) | 2019-09-10 | 2021-03-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating kras mutant cancers |
| US20230002371A1 (en) | 2019-09-13 | 2023-01-05 | Biotheryx, Inc. | Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| US20220402916A1 (en) | 2019-09-18 | 2022-12-22 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| WO2021052499A1 (zh) | 2019-09-20 | 2021-03-25 | 上海济煜医药科技有限公司 | 稠合吡啶酮类化合物及其制备方法和应用 |
| CN114502165A (zh) | 2019-09-23 | 2022-05-13 | 苏州浦合医药科技有限公司 | Shp2抑制剂及其用途 |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| TW202115062A (zh) | 2019-09-25 | 2021-04-16 | 大陸商北京加科思新藥研發有限公司 | Kras突變蛋白抑制劑 |
| WO2021058018A1 (en) | 2019-09-29 | 2021-04-01 | Beigene, Ltd. | Inhibitors of kras g12c |
| WO2021063346A1 (zh) | 2019-09-30 | 2021-04-08 | 上海迪诺医药科技有限公司 | Kras g12c抑制剂及其应用 |
| CN114555586B (zh) | 2019-10-10 | 2023-06-23 | 信达生物制药(苏州)有限公司 | Krasg12c蛋白抑制剂及其制备方法和用途 |
| JP6754125B1 (ja) | 2019-10-15 | 2020-09-09 | 学校法人東京理科大学 | Ｂｒａｐ２作用増強剤 |
| US20240139193A1 (en) | 2019-10-15 | 2024-05-02 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| US12331035B2 (en) | 2019-10-23 | 2025-06-17 | Sk Biopharmaceuticals Co., Ltd. | Bicyclic compound and use thereof |
| CN112694475B (zh) | 2019-10-23 | 2025-09-23 | 苏州泽璟生物制药股份有限公司 | 环烷基类和杂环烷基类抑制剂及其制备方法和应用 |
| EP4048671B1 (en) | 2019-10-24 | 2026-03-18 | Amgen Inc. | Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer |
| UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
| JP7601869B2 (ja) | 2019-10-30 | 2024-12-17 | ▲勁▼方医▲薬▼科技（上海）有限公司 | 置換された複素環－環系化合物、その調製方法及び医薬への応用 |
| WO2021084765A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd | 4-aminobut-2-enamide derivatives and salts thereof |
| US20230023023A1 (en) | 2019-10-31 | 2023-01-26 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| CN113286794B (zh) | 2019-11-04 | 2024-03-12 | 北京加科思新药研发有限公司 | Kras突变蛋白抑制剂 |
| AU2020377925A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202132316A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| IL322454A (en) | 2019-11-04 | 2025-09-01 | Revolution Medicines Inc | ras inhibitors |
| BR112022007535A2 (pt) | 2019-11-07 | 2022-07-12 | Chugai Pharmaceutical Co Ltd | Composto peptídico cíclico tendo ação inibitória de kras |
| CN112778301A (zh) | 2019-11-07 | 2021-05-11 | 苏州泽璟生物制药股份有限公司 | 四氢吡啶并嘧啶类抑制剂及其制备方法和应用 |
| CN114630832A (zh) | 2019-11-15 | 2022-06-14 | 四川海思科制药有限公司 | 一种嘧啶并环衍生物及其在医药上的应用 |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| CN113614080B (zh) | 2019-11-29 | 2022-06-28 | 苏州信诺维医药科技股份有限公司 | Kras g12c抑制剂化合物及其用途 |
| WO2021109737A1 (zh) | 2019-12-02 | 2021-06-10 | 上海璎黎药业有限公司 | 一种含氧杂环化合物、其制备方法及应用 |
| WO2021113595A1 (en) | 2019-12-06 | 2021-06-10 | Beta Pharma, Inc. | Phosphorus derivatives as kras inhibitors |
| WO2021120045A1 (en) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| WO2021126799A1 (en) | 2019-12-18 | 2021-06-24 | Merck Sharp & Dohme Corp. | Macrocyclic peptides as potent inhibitors of k-ras g12d mutant |
| WO2021121397A1 (zh) | 2019-12-19 | 2021-06-24 | 首药控股(北京)股份有限公司 | 取代的炔基杂环化合物 |
| IL293962B2 (en) | 2019-12-19 | 2025-10-01 | Jacobio Pharmaceuticals Co Ltd | Mutant KRAS protein inhibitors |
| CN114761408B (zh) | 2019-12-19 | 2023-09-15 | 贝达药业股份有限公司 | Kras g12c抑制剂及其在医药上的应用 |
| TR201920922A2 (tr) | 2019-12-20 | 2020-06-22 | Ankara Ueniversitesi | 3/4-((2E,6E)-3,7,11-Trimetildodeka-2,6,10-trieniltiyo)benzamid Türevi Bileşikler |
| CA3164995A1 (en) | 2019-12-20 | 2021-06-24 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CN113045565A (zh) | 2019-12-27 | 2021-06-29 | 微境生物医药科技(上海)有限公司 | 新型K-Ras G12C抑制剂 |
| JP7850663B2 (ja) | 2019-12-27 | 2026-04-23 | ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド | スピロ環含有キナゾリン化合物 |
| WO2021139678A1 (zh) | 2020-01-07 | 2021-07-15 | 广州百霆医药科技有限公司 | 吡啶并嘧啶类kras g12c突变蛋白抑制剂 |
| WO2021139748A1 (en) | 2020-01-08 | 2021-07-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Spirocyclic tetrahydroquinazolines |
| US20210269434A1 (en) | 2020-01-10 | 2021-09-02 | Incyte Corporation | Tricyclic compounds as inhibitors of kras |
| WO2021143693A1 (zh) | 2020-01-13 | 2021-07-22 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| KR102382613B1 (ko) | 2020-01-15 | 2022-04-06 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물 |
| KR102396930B1 (ko) | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
| WO2021150613A1 (en) | 2020-01-20 | 2021-07-29 | Incyte Corporation | Spiro compounds as inhibitors of kras |
| CN115003668A (zh) | 2020-01-21 | 2022-09-02 | 南京明德新药研发有限公司 | 作为kras抑制剂的大环类化合物 |
| GB202001344D0 (en) | 2020-01-31 | 2020-03-18 | Redx Pharma Plc | Ras Inhibitors |
| CN115135650A (zh) | 2020-02-20 | 2022-09-30 | 贝达医药公司 | 作为kras抑制剂的吡啶并嘧啶衍生物 |
| CN113637005B (zh) | 2020-02-24 | 2024-05-24 | 泰励生物科技（上海）有限公司 | 用于癌症治疗的kras抑制剂 |
| CN114845997B (zh) | 2020-02-24 | 2024-03-29 | 上海喆邺生物科技有限公司 | 芳香类化合物及其在制备抗肿瘤药物中的应用 |
| US20210292330A1 (en) | 2020-02-28 | 2021-09-23 | Erasca, Inc. | Pyrrolidine-fused heterocycles |
| CN114901663B (zh) | 2020-03-02 | 2024-07-02 | 上海喆邺生物科技有限公司 | 一类芳香杂环类化合物及其在药物中的应用 |
| KR20210111711A (ko) | 2020-03-03 | 2021-09-13 | 웰마커바이오 주식회사 | Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물 |
| WO2021178741A1 (en) | 2020-03-05 | 2021-09-10 | The Regents Of The University Of Michigan | Inhibitors of egfr, kras, braf, and other targets and use of the same |
| CN115397413A (zh) | 2020-03-05 | 2022-11-25 | 密歇根大学董事会 | Egfr、kras、braf和其他靶标的抑制剂及其用途 |
| AU2021233058B2 (en) | 2020-03-12 | 2024-05-16 | D3 Bio(Wuxi) Co., Ltd | Pyrimidoheterocyclic compounds and application thereof |
| TW202144345A (zh) | 2020-03-17 | 2021-12-01 | 大陸商北京加科思新藥研發有限公司 | Ｋｒａｓ突變蛋白抑制劑 |
| CA3170068A1 (en) | 2020-03-25 | 2021-09-30 | Yuli Xie | Spiro ring-containing quinazoline compound |
| WO2021197499A1 (zh) | 2020-04-03 | 2021-10-07 | 南京明德新药研发有限公司 | 八氢吡嗪并二氮杂萘啶二酮类化生物 |
| CN115803030A (zh) | 2020-04-06 | 2023-03-14 | 阿维纳斯企业公司 | 用于kras靶向降解的化合物和方法 |
| TW202144338A (zh) | 2020-04-08 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 嘧啶并二環類衍生物、其製備方法及其在醫藥上的應用 |
| AU2021254794A1 (en) | 2020-04-16 | 2022-12-15 | Incyte Corporation | Fused tricyclic KRAS inhibitors |
| WO2021216770A1 (en) | 2020-04-22 | 2021-10-28 | Accutar Biotechnology Inc. | Substituted tetrahydroquinazoline compounds as kras inhibitors |
| US20230242586A1 (en) | 2020-04-23 | 2023-08-03 | The Regents Of The University Of California | Ras inhibitors and uses thereof |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| CN115135636B (zh) | 2020-04-29 | 2024-08-23 | 北京泰德制药股份有限公司 | 喹喔啉酮衍生物作为kras g12c突变蛋白的不可逆抑制剂 |
| CA3177261A1 (en) | 2020-04-29 | 2021-11-04 | Shanghai Ringene Biopharma Co., Ltd. | Benzothiazolyl biaryl compound, and preparation method and use |
| WO2021219072A1 (zh) | 2020-04-30 | 2021-11-04 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| CN113666923A (zh) | 2020-05-15 | 2021-11-19 | 苏州泽璟生物制药股份有限公司 | 烷氧基烷基取代杂环基类抑制剂及其制备方法和应用 |
| WO2021236475A1 (en) | 2020-05-18 | 2021-11-25 | Asinex Corporation | Compounds that inhibit asparagine synthetase and their methods of use |
| TWI799871B (zh) | 2020-05-27 | 2023-04-21 | 大陸商勁方醫藥科技(上海)有限公司 | 三環并環類化合物，其製法與醫藥上的用途 |
| CA3180314A1 (en) | 2020-05-29 | 2021-12-02 | John Graeme HODGSON | Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9 |
| JP7808058B2 (ja) | 2020-06-02 | 2026-01-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体 |
| WO2021244603A1 (en) | 2020-06-04 | 2021-12-09 | Shanghai Antengene Corporation Limited | Inhibitors of kras g12c protein and uses thereof |
| US20230202981A1 (en) | 2020-06-04 | 2023-06-29 | Baskaran Pillai | Novel small molecules for targeted degradation of untargetable kras in cancer therapy |
| WO2021248082A1 (en) | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| WO2021248083A1 (en) | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| US20230026856A1 (en) | 2020-06-05 | 2023-01-26 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| WO2021248079A1 (en) | 2020-06-05 | 2021-12-09 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| US20230023009A1 (en) | 2020-06-05 | 2023-01-26 | Sparcbio Llc | Heterocyclic compounds and methods of use thereof |
| WO2021252339A1 (en) | 2020-06-08 | 2021-12-16 | Accutar Biotechnology, Inc. | Substituted purine-2,6-dione compounds as kras inhibitors |
| WO2021249563A1 (zh) | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| US20230227466A1 (en) | 2020-06-18 | 2023-07-20 | Shy Therapeutics, Llc | Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| WO2021259331A1 (zh) | 2020-06-24 | 2021-12-30 | 南京明德新药研发有限公司 | 八元含n杂环类化合物 |
| WO2022002102A1 (en) | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
| WO2022015375A1 (en) | 2020-07-16 | 2022-01-20 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2022017339A1 (zh) | 2020-07-20 | 2022-01-27 | 江苏恒瑞医药股份有限公司 | 稠合哒嗪类衍生物、其制备方法及其在医药上的应用 |
| JP7584815B2 (ja) | 2020-08-02 | 2024-11-18 | 上▲海▼▲哲▼▲イェ▼生物科技有限公司 | 抗腫瘍薬物における芳香族化合物及びその用途 |
| EP4192585A4 (en) | 2020-08-04 | 2024-08-21 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2022028492A1 (en) | 2020-08-05 | 2022-02-10 | Beigene, Ltd. | Imidazotriazine and pyrrolopyrimidine derivatives as kras g12c inhibitors |
| US20230303551A1 (en) | 2020-08-13 | 2023-09-28 | Albert Einstein College Of Medicine | N-cyclyl-sulfonamides useful for inhibiting raf |
-
2020
- 2020-08-27 MX MX2022002465A patent/MX2022002465A/es unknown
- 2020-08-27 JP JP2022513171A patent/JP7622043B2/ja active Active
- 2020-08-27 CN CN202080076261.5A patent/CN114615981B/zh active Active
- 2020-08-27 US US17/005,004 patent/US11453683B1/en active Active
- 2020-08-27 AU AU2020337938A patent/AU2020337938B2/en active Active
- 2020-08-27 BR BR112022003543A patent/BR112022003543A2/pt unknown
- 2020-08-27 WO PCT/US2020/048194 patent/WO2021041671A1/en not_active Ceased
- 2020-08-27 PH PH1/2022/550469A patent/PH12022550469A1/en unknown
- 2020-08-27 KR KR1020227009947A patent/KR20220071193A/ko active Pending
- 2020-08-27 EP EP20859068.7A patent/EP4021444A4/en active Pending
- 2020-08-27 CA CA3148745A patent/CA3148745A1/en active Pending
- 2020-08-28 TW TW109129561A patent/TWI874443B/zh active
- 2020-08-28 TW TW114103629A patent/TWI912127B/zh active
-
2022
- 2022-02-23 IL IL290845A patent/IL290845B1/en unknown
- 2022-02-23 CL CL2022000447A patent/CL2022000447A1/es unknown
- 2022-02-24 ZA ZA2022/02362A patent/ZA202202362B/en unknown
- 2022-03-29 CO CONC2022/0003782A patent/CO2022003782A2/es unknown
- 2022-07-20 US US17/869,575 patent/US11964989B2/en active Active
-
2024
- 2024-04-23 US US18/644,056 patent/US20240309020A1/en active Pending
-
2025
- 2025-01-14 JP JP2025004802A patent/JP2025063176A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025063176A5 (https=) | ||
| JP4959900B2 (ja) | 抗ウイルスピリミジンヌクレオシド類 | |
| JP2025511399A5 (https=) | ||
| JP2022545005A5 (https=) | ||
| KR100258668B1 (ko) | 2'-할로메틸리덴 유도체와 s-기 또는 m-기 특이성 항종양제를 포함하는 암치료용 조성물 | |
| RU2011142750A (ru) | Способ лечения путем применения комбинированной терапии | |
| JP2011529474A (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2008536807A5 (https=) | ||
| WO2010031265A1 (zh) | 用于治疗增生性疾病的药物组合物 | |
| JP2020522567A5 (https=) | ||
| JP2003525246A (ja) | 白金化合物とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤 | |
| KR20140096375A (ko) | 항종양제의 효과 증강제 | |
| EA003134B1 (ru) | Противоопухолевая композиция, содержащая синергическую комбинацию производного антрациклина и производного камптотецина | |
| JP2020512977A5 (https=) | ||
| JP2021523169A5 (https=) | ||
| JP2019519563A5 (https=) | ||
| JP2023546316A5 (https=) | ||
| FI2968346T3 (fi) | Menetelmiä ja koostumuksia gamma-glutamyylisyklin muokkaamiseksi | |
| JP2003523326A (ja) | トポイソメラーゼｉ阻害を有する１０，１１−ジフルオロメチレンジオキシカンプトテシン化合物 | |
| TWI638825B (zh) | 抑制癌症及病毒之化合物 | |
| JP2022531980A5 (https=) | ||
| KR100853955B1 (ko) | 아크릴로일 디스타마이신 유도체 및 국소이성화효소 ⅰ 및ⅱ 억제제를 포함하는 약제학적 조성물 | |
| JP2018511642A5 (https=) | ||
| CN110573620B (zh) | 血癌治疗剂 | |
| CN101175495B (zh) | 抗癌化合物的组合 |